Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes ... (gen received an option to obtain an excl...)

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452

Date:5/26/2009

gen received an option to obtain an exclusive license to Cytokinetics' cardiac contractility program, (including the lead drug candidate, CK-1827452). Under the terms of the agreement, Cytokinetics is eligible to receive pre-commercialization and commercialization milestone payments of up to $600 million on CK-1827452 and other products arising from the collaboration, and royalties that escalate based on increasing levels of annual net sales of products commercialized under the agreement. Cytokinetics also has the opportunity to earn increased royalties by sharing certain Phase 3 development costs. In that case, Cytokinetics could co-promote products in North America and would have an agreed role in commercialization activities in North America. The collaboration is worldwide, excluding Japan.

Development Status of CK-1827452

CK-1827452, a novel cardiac myosin activator, has been the subject of a clinical trials program comprised of multiple Phase 1 and Phase 2a trials. This program was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of both intravenous and oral formulations of CK-1827452 for the potential treatment of heart failure across the continuum of care, in both hospital and outpatient settings. Two Phase 2a clinical trials of CK-1827452 from this program have been completed, and two Phase 2a clinical trials of CK-1827452 are ongoing.

The first Phase 2a clinical trial evaluated CK-1827452 in patients with stable heart failure. Data from that trial were recently presented at the American College of Cardiology Meeting in March 2009. Cytokinetics plans to present additional analyses from this trial at a Late Breaking Trial session at the 2009 Heart Failure Congress of the European Society of Cardiology, to be held from May 30 - June 2 in Nice, France. The second Phase 2a clinical trial was designed to evaluate an intravenous formulation together with an oral fo
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years

Post Your Comments:

(Date:12/15/2009)... Sky One,Medical, Inc. ("China Sky One Medical" or ... integrated pharmaceutical company developing and producing,over-the-counter drugs in ... the Company has 30 medicines that will be ... Medical Insurance, Industrial Injury Insurance,and Maternity Insurance Medicine ... medicines treat a variety of common ailments and ...

(Date:12/15/2009)... Constant diameter NeedleProbes™ for Atomic Force Microscopy (AFM) have ... research for studies at the liquid/air interface. The NeedleProbes’ ... meniscus height, evaporation rate and viscosity - all in a ... ... (PRWEB) December 15, 2009 -- New, constant diameter NeedleProbes ...

(Date:12/15/2009)... MANOR, N.Y., Dec. 15 On January ... International Society for Medical Publication Professionals (ISMPP) will ... in London, UK. More than 100 attendees are ... forum for publication professionals, editors, publishers, medical writers ... of medical publications and the impact of guidelines ...

(Date:12/14/2009)... Colo. and THOUSAND OAKS, Calif., Dec. 14 /PRNewswire-FirstCall/ ... and Amgen Inc.(Nasdaq: AMGN ) today announced ... exclusive worldwide rights to Array,s small-molecule glucokinase activator ... Phase 1 clinical trial in patients with Type ... of the agreement, Array will receive an upfront ...

Breaking Biology Technology:China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2 China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3 New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 2 New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 3 Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2 Array BioPharma and Amgen Partner in Type 2 Diabetes 2 Array BioPharma and Amgen Partner in Type 2 Diabetes 3 Array BioPharma and Amgen Partner in Type 2 Diabetes 4 Array BioPharma and Amgen Partner in Type 2 Diabetes 5 Array BioPharma and Amgen Partner in Type 2 Diabetes 6 Array BioPharma and Amgen Partner in Type 2 Diabetes 7

[0] China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory [0] New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM [0] Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 [0] Array BioPharma and Amgen Partner in Type 2 Diabetes

... Poole, an economic and community development specialist, presented a ... 2004 Governors Conference on Economic Development . Abstaining from ... keep and grow businesses in Wisconsin. , ,Wisconsin manufacturing ... breakdown, Poole said. He cited that Wisconsin saw only ...

... Wis. -- Bone Care International, Inc. announced Tuesday Herbert Conrad ... Mazess. Mazess will remain on the board of directors. ... the U.S. Pharmaceuticals Division of Hoffmann-La Roche, Inc. He served ... Inc. from 1996 to 2003, and was a co-founder of ...

... TeraMEDICA announced today Jim Prekop as president of ... from Peoplesoft where he recently served as ... to joining Peoplesoft, Prekop spent 14 years with Dun ... Hanna.said that the move will allow him to focus ...

Other Biology Technology:Optimistic Outlook For Manufacturing 2

Optimistic Outlook For Manufacturing Bone Care Names New Chairman TeraMEDICA Appoints Prekop as New President

(Date:12/15/2009)... treating devastating brain diseases such as Alzheimer,s and Parkinson,s, ... something to help a patient. , But they come ... majority of patients with ataxia disabling disorders that ... of Florida neurologists are trying to change that with ... the National Institute of Neurological Disorders and Stroke to ...

(Date:12/15/2009)... mammoths and ancient American horses may have been ... years longer than previously thought. After plucking ancient ... team of researchers used cutting-edge techniques to uncover ... samples dated to between 7,600 and 10,500 calendar ... one population of these now-extinct mammals endured longer ...

(Date:12/15/2009)... on society. It is estimated that 100 to 150 ... and it,s likely that rip currents account for more than ... rip current research and public understanding. Rip currents are ... most people do not know how to even identify, much ... the Rip Current Symposium is to identify advancements in rip ...

[0] UF to lead national effort to help patients with rare brain disease [0] Late-surviving megafauna exposed by ancient DNA in frozen soil [0] 1st International Rip Current Symposium

... make the manufacture of products, from iridescent cosmetics, paints and ... , The tiny single-celled diatom, which first evolved hundreds of ... is iridescent in other words, the shell displays vivid ... is observed. This effect is caused by a complex network ...

... Md., October 2, 2007 The United States Pharmacopeial ... verification mark, shown at the conclusion of this announcement, ... Dr. Reddys Laboratories, Ltd. in Hyderabad, India. The ... may now use this special mark on its certificate ...

... the Woods Hole Research Center known as the Polaris Project, ... in arctic research and education, and inform the public, both ... underway in the Arctic in response to global warming. This ... the National Science Foundation, announced today. , According to Dr. ...

Other Biology News:Nature leads the way for the next generation of paints, cosmetics and holograms 2 USP awards verified mark to Dr. Reddy's Laboratories, Ltd. ingredients 2 USP awards verified mark to Dr. Reddy's Laboratories, Ltd. ingredients 3 Woods Hole Research Center to lead undergraduate initiative in the Siberian Arctic 2 Woods Hole Research Center to lead undergraduate initiative in the Siberian Arctic 3

Nature leads the way for the next generation of paints, cosmetics and holograms USP awards verified mark to Dr. Reddy's Laboratories, Ltd. ingredients Woods Hole Research Center to lead undergraduate initiative in the Siberian Arctic

Hamster serum...

... CyScribe First-Strand cDNA Labeling System ... Kit, 50 reactions. For the generation ... cDNA.Optimized reagents are packaged together for ... optimized protocols can be used for ...

... First-Strand cDNA Labeling System - dUTP ... reactions. For the generation and purification ... are packaged together for complete cDNA ... can be used for performing labeling ...

... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...

Biology Products:

Hamster serum from Equitech-Bio CyScribe First-Strand cDNA Labeling System - dCTP with CyScribe GFX Purification Kit from GE Healthcare, formerly Amersham Biosciences CyScribe First-Strand cDNA Labeling System - dUTP with CyScribe GFX Purification Kit from GE Healthcare, formerly Amersham Biosciences Affinity Purification (antigen specific) from Covance Research Products, Inc

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes ...(gen received an option to obtain an excl...)